Skandinaviska Enskilda Banken AB publ lifted its holdings in shares of DaVita Inc. (NYSE:DVA – Free Report) by 256.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 162,233 shares of the company’s stock after buying an additional 116,758 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned approximately 0.20% of DaVita worth $24,301,000 as of its most recent SEC filing.
Other large investors also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. acquired a new stake in DaVita in the 4th quarter valued at about $41,000. Quarry LP acquired a new stake in shares of DaVita in the third quarter valued at $60,000. Venturi Wealth Management LLC increased its stake in DaVita by 59.8% during the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company’s stock worth $61,000 after purchasing an additional 152 shares during the period. Versant Capital Management Inc increased its stake in DaVita by 58.7% during the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock worth $68,000 after buying an additional 169 shares during the period. Finally, Blue Trust Inc. raised its stake in shares of DaVita by 39.7% in the fourth quarter. Blue Trust Inc. now owns 461 shares of the company’s stock valued at $76,000 after acquiring an additional 131 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.
DaVita Stock Performance
Shares of DVA opened at $141.23 on Friday. The company’s 50 day simple moving average is $159.28 and its 200-day simple moving average is $157.79. DaVita Inc. has a 12-month low of $125.64 and a 12-month high of $179.60. The firm has a market cap of $11.30 billion, a PE ratio of 13.15, a price-to-earnings-growth ratio of 1.07 and a beta of 0.99. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18.
Analyst Ratings Changes
DVA has been the subject of several recent research reports. Sanford C. Bernstein set a $184.00 price objective on DaVita in a research note on Friday, February 21st. Barclays lifted their price target on shares of DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 18th. Finally, Cowen reissued a “hold” rating on shares of DaVita in a research report on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $166.33.
Check Out Our Latest Stock Analysis on DVA
About DaVita
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading
- Five stocks we like better than DaVita
- The 3 Best Fintech Stocks to Buy Now
- 3 Undervalued Stocks You Can Buy at a Discount Now
- Basic Materials Stocks Investing
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.